Preview Mode Links will not work in preview mode

Medscape InDiscussion: Schizophrenia

Jul 20, 2023

Drs John M. Kane and Mitchell Arnovitz discuss assessment of patients for negative symptoms of schizophrenia and the potential of MDMA in alleviating these symptoms in supervised treatment settings.

Relevant disclosures can be found with the episode show notes on Medscape ( The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals.



MDMA for the Treatment of Negative Symptoms in Schizophrenia

MDMA (Ecstasy/Molly)

The NIMH-MATRICS Consensus Statement on Negative Symptoms

The Current Conceptualization of Negative Symptoms in Schizophrenia


An Assessment of Five (PANSS, SAPS, SANS, NSA-16, CGI-SCH) Commonly Used Symptoms Rating Scales in Schizophrenia and Comparison to Newer Scales (CAINS, BNSS)

Ecological Momentary Assessment

Schizophrenia Medication

Cariprazine, a Broad-Spectrum Antipsychotic for the Treatment of Schizophrenia: Pharmacology, Efficacy, and Safety

DRD3 Dopamine Receptor D3 [Homo sapiens (human)]


Transcranial Magnetic Stimulation: A Review of Its Evolution and Current Applications


Making MDMA a Medicine (II) (Re)scheduling for Schedule I Substances

Vesicular Monoamine Transporter 2 (VMAT2) Inhibitors

Metaplasticity: Tuning Synapses and Networks for Plasticity

MDMA-Assisted Psychotherapy for Treatment of Posttraumatic Stress Disorder: A Systematic Review With Meta-Analysis

Reduction in Social Anxiety After MDMA-Assisted Psychotherapy With Autistic Adults: A Randomized, Double-Blind, Placebo-Controlled Pilot Study

Prefrontal Cortex-Nucleus Accumbens Interaction: In Vivo Modulation by Dopamine and Glutamate in the Prefrontal Cortex

Serotonin Syndrome